Affera, Inc. – Innovative Solutions for the Treatment of Cardiac …
Apr 24, 2023 · Affera is a medical technology company dedicated to delivering innovative solutions to address the rapidly growing cardiac arrhythmia market. Affera is developing a comprehensive …
Publications – Affera, Inc.
May 8, 2020 · Affera is developing a comprehensive integrated platform to efficiently deliver durable therapy for a broad set of cardiac arrhythmia patients.
News – Affera, Inc.
Dec 19, 2019 · Affera’s Technology for Cardiac Arrhythmia Treatment Highlighted at the 2020 Heart Rhythm Society Late-Breaking Clinical Trial Session and Three Simultaneous Publications
News Archives – Affera, Inc.
May 12, 2020 · Affera’s Technology for Cardiac Arrhythmia Treatment Highlighted at the 2020 Heart Rhythm Society Late-Breaking Clinical Trial Session and Three Simultaneous Publications
Privacy Policy – Affera, Inc.
The following policy outlines how Affera, Inc. collects and uses information about visitors to this website.
News Archives – Affera, Inc.
Affera’s Technology for Cardiac Arrhythmia Treatment Highlighted at the 2020 Heart Rhythm Society Late-Breaking Clinical Trial Session and Three Simultaneous Publications
Publications Archives – Affera, Inc.
Preclinical assessment of the feasibility, safety, and lesion durability of a novel ‘single-shot’ pulsed field ablation catheter for pulmonary vein isolation by ncormierdesign | Feb 16, 2023 | Publications
Publications Archives – Page 2 of 3 – Affera, Inc.
A Lattice-Tip Focal Ablation Catheter that Toggles Between Radiofrequency and Pulsed Field Energy to Treat Atrial Fibrillation: A First-in-Human Trial by ncormierdesign | May 8, 2020 | Publications
News Archives – Page 2 of 2 – Affera, Inc.
Affera Announces World’s First Successful Focal Pulsed Field Ablation in Patients
Affera, Inc.
The post Preclinical assessment of the feasibility, safety, and lesion durability of a novel ‘single-shot’ pulsed field ablation catheter for pulmonary vein isolationappeared first on Affera, Inc..